The key advantage of PROTACs is their catalytic mode of action. This translates into promising properties like prolonged pharmacological effects and dose reduction of administered PROTACs compared to a classical inhibitor. These benefits potentially elongate treatment intervals and reduce side effects. In addition, PROTACs can also overcome cancer cell resistances to occupancy-driven inhibitors. For example, target amplification or overexpression can effectively be addressed by PROTACs. Moreover, PROTACs can bypass drug target alterations since they do not rely on tight-binding POI ligands. Even weak binding ligands can sufficiently form a productive ternary complex, supported by stabilizing protein-protein interactions (PPIs). These